“Your issue of clinical science and corruption and integrity comes in because most of the simple molecules are off-patent such that it is not as easy to print money with them as it is with a new (untested) mRNA product.”
That can happen as easily with new small molecule drugs.
Not with the old ones, which have their risks, side effects, and interactions well characterized.